Key Highlights

  • Shares fell 14.16% to USD 4.85 in regular trading on November 3, 2026, from about USD 5.65 on November 2 (calculated).
  • No company announcement dated November 2 or November 3, 2026 was identified.
  • Vivani would own about 77.98% of the combined company after the Cortigent merger, excluding financing.
  • The Merger requires a financing of USD 10.0 million to USD 15.0 million.
  • Cash was about USD 75,000 and the quarterly net loss about USD 914,000 for the June 2026 quarter.

What Moved ClearOne Shares Today (down USD 0.8000, 14.16%)

ClearOne (NASDAQ:CLRO) was down 14.16% to USD 4.85 in regular trading on November 3, 2026. The Monday, November 2, 2026 close was about USD 5.65 (calculated), which was itself roughly 66% above the prior session's implied level near USD 3.41 (calculated), so Tuesday's decline gives back part of that rally.

No company announcement dated November 2 or November 3, 2026 was identified. The screen showed Volume of about 464,250 shares and a Market Capitalisation of about USD 12.98 million. With about 2.68 million shares outstanding and a public float reported at roughly 714,000 shares, modest trading can swing the price widely.

The Cortigent Merger in Detail

Under an agreement announced July 2, 2026, Cortigent, Inc., a Subsidiary of Vivani Medical (NASDAQ:VANI), would become a Wholly Owned Subsidiary of ClearOne. On October 30, 2026 Vivani said closing still awaited final regulatory approval after an earlier expectation of an October close.

A regulatory filing says Vivani would hold about 77.98% of the combined company, through 12,500,000 consideration shares out of about 16,030,412 total, while existing ClearOne holders would own about 16.69%. Closing is conditioned on a financing of USD 10.0 million to USD 15.0 million in units of one share and one warrant, Nasdaq approval of the combined company's listing and ClearOne net cash of at least USD 50,000 excluding financing proceeds.

Business Background and Recent Updates

ClearOne once made audio conferencing and collaboration products. It sold those Assets to Biamp Systems for USD 3.0 million gross, closing on October 24, 2025, and said it would stay public. A 1-for-15 Reverse Stock Split took effect on June 9, 2025.

Cortigent is a pre-revenue neurostimulation company that was formerly part of Second Sight Medical Products. Its Orion cortical visual prosthesis and stroke recovery system remain investigational.

For the June 2026 quarter, market data shows a net loss of about USD 914,000 and cash of about USD 75,000, and the auditors have expressed substantial doubt about the company's ability to continue as a going concern.

Listing and Balance Sheet Risks

Nasdaq staff determined on October 8, 2026 to delist the shares because ClearOne did not meet the USD 2.5 million stockholders' Equity requirement or complete its compliance plan from May 22, 2026. The company said it would request a hearing by October 15, 2026, which pauses any suspension while a panel considers a new plan.

The majority holder has provided a Loan of up to USD 1 million due December 30, 2026. As a Penny Stock under USD 5, ClearOne carries heavy volatility, Liquidity and dilution risk, and the merger filing says a reverse split may be needed to meet the listing bid price rule.

What to Watch Next

Markers include any announcement of regulatory clearance, pricing of the financing, the hearing outcome and any reverse split ratio. The merger outside date falls around late December 2026 (calculated from filing terms).

Without fresh disclosure, price action may keep following the small float more than company news.